Related Experiment Videos
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388)
Cancer Treatment Reports
|February 1, 1976
Summary
Dacarbazine (DTIC) showed a 16% objective response rate in malignant melanoma patients. Combinations with nitrosoureas offered no additive benefit, and DTIC was less effective as a secondary treatment.
Area of Science:
- Medical Oncology
- Clinical Pharmacology
- Cancer Research
Background:
- Malignant melanoma is a significant health concern.
- Chemotherapy plays a role in melanoma treatment.
- Dacarbazine (DTIC) is a chemotherapeutic agent used for melanoma.
Purpose of the Study:
- To evaluate the efficacy of Dacarbazine (DTIC) in malignant melanoma.
- To assess the impact of DTIC in combination therapies.
- To identify factors influencing treatment response and survival.
Main Methods:
- Analysis of four randomized controlled clinical trials.
- Evaluation of DTIC monotherapy and combination regimens.
- Correlation analysis of response rates with patient characteristics and disease factors.
Main Results:
- Consistent objective response rate of 16% for DTIC in malignant melanoma.
- No additive effect observed when combining DTIC with nitrosoureas.
- DTIC demonstrated a lower response rate (3%) as a secondary treatment.
- Survival benefit was correlated with treatment response, sex, ambulatory status, and disease site.
- Significant variation in response rates (3%-40%) across different patient contributors.
Conclusions:
- Dacarbazine (DTIC) has a modest objective response rate in malignant melanoma.
- Combination therapy with nitrosoureas does not enhance DTIC's efficacy.
- Patient-specific factors and disease characteristics influence outcomes.
- Controlled randomized trials are essential for validating chemotherapy efficacy in melanoma.